ClinicalTrials.gg
CompletedNCT05492734Updated Sep 2, 2022

A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling

A Phase 1 interventional study of EDG-5506 in Muscular Dystrophies, sponsored by Edgewise Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-02.

Sponsored by Edgewise Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2022, 4 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
19 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Muscular Dystrophies with a site in United States — 32 open to participants now, 43 under way, 2 of them phase 3. Muscular Dystrophies · United States.

Enrollment
62nd of 80
10 · median 41
Started
2022
with 12 others
Phase 1
15 of 127
1 open now
Registered
95th of 127
by date

Among the 127 studies in Muscular Dystrophies with a site in United States, this one is the 62nd largest by enrollment of the 80 interventional ones that give a count, is one of 13 that started in 2022, is one of 15 in phase 1, and was the 95th registered.

Muscular Dystrophies

224 studies on the registry are indexed under Muscular Dystrophies; 48 are open to participants now.

Browse Muscular Dystrophies studies →

Open to participants now

32 of the 127 studies in Muscular Dystrophies with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Muscular Dystrophies studies recruiting now, 14 (37%) set no upper age limit and 15 (39%) stop at 75 or younger; 24 take children under 18; 7 take healthy volunteers.

This study: 19 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Muscular Dystrophies with a site in United States, or all of them as a file.
02

Study summary

This is a Phase I, open-label, single-dose, 1-period study to compare EDG-5506 concentrations measured from venous and capillary blood sampling in healthy adult subjects.

EDG-5506 is an investigational product designed to selectively modulate a fast skeletal muscle motor protein called myosin that is part of the contraction machinery of the damage-prone muscle fibers.

Read the detailed description

Ten (10) healthy, adult male and female (of non-childbearing potential only) participants will be enrolled in the single-site study. Participants will receive a single oral dose of EDG-5506 on Day 1. Serial blood sampling will be collected pre-dose and up to 26 hours post-dose using venous blood sampling by venipuncture and capillary blood sampling by a capillary blood self-sampling device. On Day 3, participants will self-collect a capillary blood sample at home. The final on-site visit will be on Day 7 when a last blood sample will be collected using venous blood sampling by venipuncture and capillary blood sampling by a capillary blood self-sampling device.

03

Conditions studied

  • Muscular Dystrophies

Browse trials for

Keywords

  • Healthy Volunteers
04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, adult, males or females, aged 19-55 years (inclusive) at the Screening visit.
  2. Females must be of non-. Males with female partners must use a medically accepted regimen or abstain from sexual intercourse for 90 days after dosing.
  3. Non-smoker and must not have used any tobacco products within 3 months prior to the Screening visit.
  4. Body weight greater than 50 kg and (BMI) between 18.0 and 30.0 kg/m2 inclusive at the Screening visit.
  5. Medically healthy with no findings for oculofacial and proximal limb strength assessments and swallowing function assessment, medical history, physical examination, laboratory profiles, vital signs, and ECGs.

Exclusion criteria

Exclusion Criteria:

  1. History of, or physical examination findings indicating endocrine, neurological, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases that, in the opinion of the PI, would render the subject being unsuitable for the study.
  2. Female participants with a positive pregnancy test at the screening visit or are lactating.
  3. Poor venous access and/or cannot tolerate venipuncture.
  4. Unable to refrain from or anticipates the use of any drugs (including prescription and non-prescription medications, herbal remedies, vitamin supplements, or grapefruit/Seville orange containing products) beginning 14 days prior to dosing. Any drugs known to be moderate or strong inducers of enzymes cannot be used within 28 days prior to dosing.
  5. Participation in any other drug study within 30 days prior to dosing.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Treatment

    Drug: EDG-5506

    Drug: EDG-5506

Interventions

06

What researchers measure

Primary outcomes

  1. Difference in area under the concentration-time curve (AUC0-24, AUC0-26, AUC0-144 and AUC0-t) measurements for EDG-5506 in blood collected by capillary blood self-sampling versus venous blood sampling

    Time frame: 7 days

  2. Plasma maximum measured drug concentration (Cmax) measurements for EDG-5506 in blood collected by capillary blood self-sampling versus venous blood sampling

    Time frame: 7 days

  3. Time of maximum concentration (Tmax) measurements for EDG-5506 in blood collected by capillary blood self-sampling versus venous blood sampling

    Time frame: 7 days

Secondary outcomes

  1. Area under the concentration-time curve (AUC0-24, AUC0-26, AUC0-144 and AUC0-t) measurements for EDG-5506 in plasma.

    Time frame: 7 days

  2. Plasma maximum measured drug concentration (Cmax) measurements for EDG-5506 in plasma.

    Time frame: 7 days

  3. Time of maximum concentration (Tmax) measurements for EDG-5506 in plasma.

    Time frame: 7 days

  4. Incidence of treatment-emergent adverse events

    Time frame: 7 days

  5. Incidence of abnormal clinical laboratory test results

    Time frame: 7 days

  6. Incidence of abnormal vital signs

    Time frame: 7 days

  7. Incidence of abnormal electrocardiograms (ECGs)

    Time frame: 7 days

07

Study locations

1 site
  • Celerion, Inc.
    Lincoln, Nebraska 68502, United States
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Aug 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2022
First posted
Aug 8, 2022
StartActual
Aug 12, 2022
Primary completionActual
Aug 19, 2022
CompletionActual
Aug 19, 2022
Last update
Sep 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05492734
Lead sponsor
Edgewise Therapeutics, Inc.
Responsible party
Sponsor
First posted
Aug 8, 2022
Start date
Aug 12, 2022
Primary completion
Aug 19, 2022
Completion
Aug 19, 2022
Last update
Sep 2, 2022

Study contacts

Sam Collins, MBBS, PhD
study chair · Edgewise Therapeutics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sevasemten

Start the discussion